KOL Knockout: Glaucoma Edition - Personalized Treatment Plans in Medical Glaucoma Management Round 1

KOL Knockout Glaucoma Edition  Personalized Treatment Plans in Medical Glaucoma Management  Round 1
Media formats available:
Details
Presenters
  • Overview

    This fun and exciting virtual CME program focusing on glaucoma is a game show-style quiz competition that features key opinion leaders (KOLs) as contestants. Hosted by Program Chair Douglas Rhee, MD, the first of three rounds will feature Jody Piltz-Seymour, MD, Nathan M. Radcliffe, MD, and Arsham Sheybani, MD, as contestants.

    This activity is supported by an unrestricted educational grant from Aerie Pharmaceuticals.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the MOA of novel therapeutics and classes of drugs.
    • Restate the most common side effects of novel therapeutics and explain the likelihood of achieving target intraocular pressure with monotherapy compared with combination regimens
    • Discuss the differences of branded versus generic glaucoma agents and identify patients at heightened risk for loss to follow-up.
    • Evaluate and explain to patients the latest available treatments and determine which option is best for each patient.
    • Accreditation

      Provided by Evolve Medical Education 

      Accreditation Statement

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

       

      Credit Designation Statement

      Evolve Medical Education, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Evolve is an approved COPE Administrator. This activity, COPE Activity Number 122144, is accredited by COPE for continuing education for optometrists for 1.5 hours.
      COPE Course ID:  73414-GL
      COPE Activity ID:  122144

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Douglas J. Rhee, MD

      Douglas J. Rhee, MD

      Chair, Department of Ophthalmology and Visual Sciences

      Director, University Hospitals Eye Institute

      Case Western Reserve University School of Medicine

      Cleveland, OH


      Nathan M. Radcliffe, MD

      Nathan M. Radcliffe, MD

      Glaucoma and Cataract Specialist
      Associate Professor of Ophthalmology
      Mount Sinai School of Medicine
      Medical Director
      New York Eye Surgery Center
      New York, NY


      Jody Piltz-Seymour, MD

      Jody Piltz-Seymour, MD

      Valley Eye Professionals, LLC 

      Wills Eye Hospital Glaucoma Service

      Clinical Professor, Perelman School of Medicine, University of Pennsylvania 

      Philadelphia, PA


      Arsham Sheybani, MD

      Arsham Sheybani, MD

      Associate Professor Professor of Ophthalmology and Visual Sciences

      Washington University School of Medicine

      St. Louis, MO


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Douglas J. Rhee, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Advisory Board: Ocular Therapeutix. Consultant: Aerie Pharmaceuticals, Allergan, and Ivantis. Grant/Research Support: Allergan, Glaukos, and Ivantis. Speaker’s Bureau: Aerie and Ivantis.

      Nathan M. Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Carl Zeiss Meditec, CATS, Ellex, ELT Sight, Equinox, Eyepoint, Glaukos Corporation, IRIDEX, Ivantis, Kala, Lumenis, New World Medical, Novartis Pharma AG, Ocular Science, Ocular Therapeutix, Omeros Corporation, Quantel Medical, Reichert, Santen, Shire, Sight Sciences, Spyglass, THEA, and ViaLase. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Eyepoint, Glaukos Corporation, IRIDEX, Ivantis, Kala, Lumenis, New World Medical, Novartis Pharma AG, Reichert, and Sight Sciences. Stock/Shareholder: CATS, ELT Sight, Equinox, Ivantis, Sight Sciences, and Spyglass.

      Jody Piltz-Seymour, MD, has had a financial agreement or affiliation during the past year with the following inelegible companies in the form of Consultant and Speaker's Bureau: Aerie Pharmaceuticals.

      Arsham Sheybani, MD, has had a financial agreement or affiliation during the past year with the following ineligible companies in the form of Consultant: Alcon, Allergan, Ivantis, and Santen. Grant/Research Support: Allergan.

      The Evolve staff, planners and peer reviewer have no financial relationships with commercial interests.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Aerie Pharmaceuticals.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free